Blood tests may predict lung cancer drug success
NCT ID NCT04557007
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study monitored drug levels in the blood of 80 patients with advanced non-small cell lung cancer who were receiving pembrolizumab (immunotherapy) alone or with chemotherapy. Researchers wanted to see if drug levels were linked to how well the cancer responded or if side effects occurred. The study was stopped early, but the data may help guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St Olavs University Hospital
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.